As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower ...

Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare ...

Shuren, who retired from his spot leading the FDA’s Center for Devices and Radiological Health (CDRH) in 2024, said last week ...

Just after PureTech Health confirmed it was in talks with Nordic Capital regarding a possible buyout, Nordic quickly set the record straight with its own announcement that it does not intend to mak | ...

As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German ...

J&J’s new pivotal study in coronary artery disease, dubbed FORWARD CAD, will test a cardiac-focused version of the Javelin as ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

| Facing “build versus buy,” or “rent versus own” for integration? Get a guide to the considerations for your organization’s ...

NashBio, a pioneer in genomics and real-world data, is transforming life sciences research by making complex healthcare data more accessible. | NashBio is transforming life sciences by making complex ...